Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 11.98%3.63B | 11.53%2.3B | 14.28%1.1B | 6.10%4.45B | 9.91%3.24B | 15.84%2.07B | 11.99%965.06M | -7.40%4.2B | -12.66%2.95B | -15.10%1.78B |
| Operating income | 11.53%2.3B | 6.10%4.45B | 15.84%2.07B | -7.40%4.2B | -15.10%1.78B | |||||
| Cost of sales | ---- | -14.03%-1.88B | ---- | -5.44%-3.57B | ---- | -9.64%-1.65B | ---- | 9.95%-3.39B | ---- | 14.26%-1.5B |
| Operating expenses | -14.03%-1.88B | -5.44%-3.57B | -9.64%-1.65B | 9.95%-3.39B | 14.26%-1.5B | |||||
| Gross profit | 1.74%428.52M | 8.86%878.65M | 48.75%421.19M | 5.12%807.14M | -19.29%283.15M | |||||
| Selling expenses | ---- | 8.34%-56.81M | ---- | -25.63%-131.43M | ---- | -33.02%-61.98M | ---- | -12.83%-104.61M | ---- | -1.56%-46.6M |
| Administrative expenses | ---- | -33.41%-158.08M | ---- | -26.56%-241.55M | ---- | -67.42%-118.49M | ---- | -46.82%-190.85M | ---- | 12.39%-70.78M |
| Research and development expenses | ---- | 4.94%-163.14M | ---- | -7.29%-330.08M | ---- | -23.23%-171.61M | ---- | -4.04%-307.66M | ---- | -2.55%-139.26M |
| Impairment and provision | ---- | -2,057.84%-2.2M | ---- | 45.93%-1.21M | ---- | 91.08%-102K | ---- | -1,044.30%-2.24M | ---- | -318.68%-1.14M |
| -Other impairment is provision | ---- | -2,057.84%-2.2M | ---- | 45.93%-1.21M | ---- | 91.08%-102K | ---- | -1,044.30%-2.24M | ---- | -318.68%-1.14M |
| Special items of operating profit | ---- | 135.19%56.83M | ---- | 149.57%152.39M | ---- | 10.87%24.16M | ---- | 5.78%61.06M | ---- | -31.55%21.79M |
| Operating profit | 12.82%105.12M | 24.32%326.76M | 97.53%93.18M | -14.49%262.83M | -60.67%47.17M | |||||
| Financing income | ---- | -29.02%10.35M | ---- | -12.46%26.37M | ---- | -2.16%14.59M | ---- | 78.23%30.12M | ---- | 125.73%14.91M |
| Financing cost | ---- | 11.95%-35.24M | ---- | -17.38%-74.38M | ---- | -49.47%-40.02M | ---- | -107.28%-63.37M | ---- | -207.84%-26.78M |
| Share of profits of associates | ---- | 104.08%259K | ---- | -167.80%-58.21M | ---- | 47.06%-6.34M | ---- | 15.27%-21.74M | ---- | -16.76%-11.98M |
| Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -41.20%-28.39M | ---- | ---15.8M |
| Earning before tax | 31.10%80.49M | 22.89%220.53M | 715.88%61.4M | -27.62%179.46M | -93.01%7.53M | |||||
| Tax | ---- | -75.04%-50.28M | ---- | -32.69%-66.19M | ---- | -77.26%-28.72M | ---- | 35.73%-49.88M | ---- | 26.66%-16.2M |
| After-tax profit from continuing operations | 3.88%104.59M | -7.53%30.21M | -38.80%6.24M | 19.12%154.35M | 117.79%100.68M | 476.45%32.67M | 209.72%10.2M | -23.93%129.57M | -65.81%46.23M | -110.15%-8.68M |
| Earning after tax | -7.53%30.21M | 19.12%154.35M | 476.45%32.67M | -23.93%129.57M | -110.15%-8.68M | |||||
| Minority profit | ---- | -977.03%-1.3M | ---- | 1.32%613K | ---- | -45.79%148K | ---- | -16.32%605K | ---- | -26.02%273K |
| Profit attributable to shareholders | -3.11%31.51M | 19.20%153.73M | 463.32%32.52M | -23.97%128.97M | -110.52%-8.95M | |||||
| Basic earnings per share | -4.35%0.0044 | 19.23%0.0217 | 453.85%0.0046 | -24.79%0.0182 | -110.57%-0.0013 | |||||
| Diluted earnings per share | -4.35%0.0044 | 19.23%0.0217 | 453.85%0.0046 | -24.17%0.0182 | -110.66%-0.0013 | |||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.